Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia”
2021; Wiley; Volume: 41; Issue: 3 Linguagem: Inglês
10.1002/npr2.12193
ISSN2574-173X
Tópico(s)Treatment of Major Depression
ResumoNeuropsychopharmacology ReportsVolume 41, Issue 3 p. 266-324 GUIDELINESOpen Access Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia" Japanese Society of Neuropsychopharmacology, Corresponding Author Japanese Society of Neuropsychopharmacology jsnp@aeplan.co.jp Correspondence Japanese Society of Neuropsychopharmacology Email: jsnp@aeplan.co.jpSearch for more papers by this author Japanese Society of Neuropsychopharmacology, Corresponding Author Japanese Society of Neuropsychopharmacology jsnp@aeplan.co.jp Correspondence Japanese Society of Neuropsychopharmacology Email: jsnp@aeplan.co.jpSearch for more papers by this author First published: 12 August 2021 https://doi.org/10.1002/npr2.12193AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat English translation team: (affiliation as of May 2021) Ryota Hashimoto, Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry Junichi Iga, Department of Neuropsychiatry, Ehime University Graduate School of Medicine Ken Inada, Department of Psychiatry, Tokyo Women's Medical University Taro Kishi, Department of Psychiatry, Fujita Health University School of Medicine Hiroshi Kimura, Department of Psychiatry, International University of Health and Welfare/Gakuji-kai Kimura Hospital Yuki Matsuda, Department of Psychiatry, Jikei University School of Medicine Nobumi Miyake, Department of Neuropsychiatry, St. Marianna University School of Medicine Kiyotaka Nemoto, Department of Psychiatry, Faculty of Medicine, University of Tsukuba Shusuke Numata, Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University Shinichiro Ochi, Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine Hideki Sato, National Center Hospital, National Center of Neurology and Psychiatry Seiichiro Tarutani, Department of Psychiatry, Shin-Abuyama Hospital, Osaka Institute of Clinical Psychiatry Hiroyuki Uchida, Department of Neuropsychiatry, Keio University School of Medicine English translation team: (COI as of 2018-2020) Ryota Hashimoto: Received research grants from Otsuka Pharmaceutical Co., Ltd., Japan Tobacco Inc., and Takeda Pharmaceutical Company Ltd.; rewards for lectures from Takeda Pharmaceutical Company Ltd., Lundbeck Japan K.K., Dainippon Sumitomo Pharma Co., Ltd., and Mochida Pharmaceutical.Co., Ltd.; manuscript fees for writing from Dainippon Sumitomo Pharma Co., Ltd. Junchi Iga: Received rewards for lectures from Otsuka Pharmaceutical Co. Ltd., Meiji Seika Pharma Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Pharmaceutical Industry Co. Ltd., Shionogi & Co. Ltd., Mochida Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mylan Inc., Sawai Pharmaceutical Co. Ltd., Novartis Pharma K.K., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Sanofi K.K., Viatris Inc., and Yoshitomiyakuhin Co. Ken Inada: Received research grants, rewards for lectures, manuscript fees for writing, and donations from Astellas Pharma Inc., Eisai Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Pfizer Inc., Meiji Seika Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Taro Kishi: Received speaker's honoraria from Sumitomo Dainippon, Otsuka, Eisai, Daiichi Sankyo, Janssen, Takeda, Kyowa, Kissei, Meiji, Pfizer, Mochida, Eli Lilly, MSD, Janssen, and Tanabe-Mitsubishi (Yoshitomi); as well as research grants from Eisai, the Japanese Ministry of Health, Labour and Welfare, Grant-in-Aid for Scientific Research, and Fujita Health University School of Medicine. Hiroshi Kimura: Received rewards for lectures from Otsuka Pharmaceutical Co. Ltd., Meiji Seika Pharma Co. Ltd. and Janssen Pharmaceutical K.K., Yuki Matsuda: Received rewards for lectures from Meiji Seika Pharma Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Kyowa Pharmaceutical Industry Co. Ltd., and Sumitomo Dainippon Pharma Co. Ltd. Nobumi Miyake: Received rewards for lectures from Meiji Seika Pharma Co. Ltd., and Sumitomo Dainippon Pharma Co. Ltd. Kiyotaka Nemoto: Received rewards for lectures from Eisai Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Eli Lilly Japan K.K., Pfizer Inc., Meiji Seika Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., and Lundbeck Japan K.K. Shusuke Numata: Received research grants, rewards for lectures, and donations from Astellas Pharma Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Pfizer Inc., Meiji Seika Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Kyowa Pharmaceutical Industry Co., Ltd., Takeda Pharmaceutical Company Limited., and Yoshitomiyakuhin Co. Shinichiro Ochi: Received rewards for lectures from Dainippon Sumitomo Pharma Co. Ltd., Meiji Seika Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., and Kowa Company, Ltd. Hideki Sato: Received research grants from Nippon Boehringer Ingelheim Co. Ltd., Lundbeck Japan K.K., Biogen Japan Ltd., and Mitsubishi Tanabe Pharma Corporation. Seiichiro Tarutani: Received rewards for lectures from Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Meiji Seika Pharma Co. Ltd., Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Hiroyuki Uchida: Received grants from Eisai, Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, Daiichi Sankyo Company, Mochida Pharmaceutical, and Meiji-Seika Pharma; speaker's honoraria from Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, Eisai, and Meiji-Seika Pharma; and advisory panel payments from Dainippon-Sumitomo Pharma within the past three years. Before reading this guideline (For experts, patients, families, and supporters) This guideline was written for specialists in the treatment of schizophrenia, but patients, as well as their families and supporters, may also use this guideline. Therefore, a very simple explanation will first be given on the aims of this guideline. This guideline shows the drug-type selection criteria for patients with a clear diagnosis of schizophrenia when starting drug treatment. There are a few elements to keep in mind when reading this guideline. The first is that this guideline is for patients with a clear diagnosis of schizophrenia. There are cases in clinical settings where a patient may have similar symptoms but is not affected by schizophrenia, particularly in the early stages of the disease, when it may not be possible to clearly diagnose schizophrenia. This guideline cannot be applied in such cases. There may also be cases where the criteria in this guideline are not applicable due to characteristics of comorbidities, even if schizophrenia was diagnosed. The second point to consider is that this guideline does not indicate that schizophrenia can be treated with pharmacological therapy alone. Schizophrenia is treated through a combination of pharmacological therapy and psychosocial therapy. Either pharmacological therapy or psychosocial therapy may be more effective depending on the types of symptoms and the time of illness. The skillful combination of both therapies can improve cerebral and psychosocial dysfunction in schizophrenia and increase the effectiveness of treatment. For this reason, the combination of pharmacological and psychosocial therapy is a major premise of schizophrenia treatment. Sufficient results cannot be expected from treatment if only one of these therapies is conducted. Furthermore, the sense of security obtained from reliable human relationships and stable living conditions is the basis of this specialized treatment. This aspect will not be repeated again in each guideline to avoid confusion. As a result, one may have the impression from reading the individual texts that it is recommended to treat schizophrenia with pharmacological therapy alone, or that pharmacological therapy has a larger effect than other therapies. This is not the aim of the guideline, and we hope that there is no confusion on this point. The third point is that this guideline discusses general theories. The pathology of schizophrenia varies in each patient. Living conditions also vary for each patient. Furthermore, drug effects and side effects are also very individual. A guideline is the result of averaging this variability. For this reason, there may be situations where the recommendations in this guideline do not apply for the specific individual case. It cannot be determined that a patient receives inappropriate treatment solely based on the fact that the guideline recommendations are not being followed. Specialized decisions on an individual level for each treatment situation are prioritized over following this guideline. The word "guideline" may give the impression that this is a set of rules, but understanding this text in this way is not correct. This guideline is significant and useful in the sense that it is a summary of the experiences of many experts studying and treating many patients, but it is not a set of rules that should be obeyed unconditionally. This guideline has value as a single document to be used as a basis or reference for experts to conduct actual treatment, as well as an opportunity for patients and their families to discuss treatment options together with the expert. Instead of patients and their families unilaterally accepting the guideline or the expert's decisions, the basis of treatment for mental illness, including schizophrenia, is for both parties to discuss their hopes and thoughts and agree on a treatment policy. Only by using this guideline for this purpose, its true intention can be realized. The objective of schizophrenia treatment is to effectively face the symptoms and illness, strive to achieve a lifestyle that the individual wants, and find a way of life that is unique to that individual through this type of collaboration. Introduction Background of creating the Guideline for Pharmacological Therapy of Schizophrenia Guidelines for schizophrenia treatment have been created in various countries and have been translated and used in Japan as well. However, the available drugs and their administration and the medical system can vary between Japan and other countries. Therefore, a clinical guideline that is aligned with the medical circumstances in Japan was needed. There have been previous clinical guidelines in Japan that relied on expert opinion, but there are none based on scientific evidence. For this reason, a clinical guideline that gathers the findings obtained to date and is based on scientific evidence was needed. With this in mind, the Japanese Society of Neuropsychopharmacology formed a Task Force of Guideline for Pharmacological Therapy of Schizophrenia and create the guideline. It should be stated once again that schizophrenia treatment is not based on pharmacological therapy alone. Comprehensive treatment such as psychosocial therapy and collaborations with medical welfare is necessary. It is self-evident that creating a comprehensive treatment guideline is desirable, but we have decided to create a guideline for pharmacological therapy for which there is relatively ample evidence as a first step for the creation of a comprehensive guideline. Members of the Japanese Society for Schizophrenia Research also participated in the creation of this guideline and were mainly in charge of writing the "Before reading this guideline" section in the introduction. Members of the task force at the time of the initial creation of the Guideline for Pharmacological Therapy of Schizophrenia at 2015 Chair Jun Ishigooka President, Japanese Society of Neuropsychopharmacology/Chief, CNS Yakuri Research Institute Vice-chair Nakao Iwata Professor, Department of Psychiatry, Fujita Health University School of Medicine Ichiro Kusumi Professor, Department of Psychiatry, Hokkaido University Graduate School Atsuo Nakagawa Specially appointed lecturer, Clinical and Translational Research Center, Keio University Seiya Miyamoto Associate Professor, Department of Neuropsychiatry, St. Marianna University School of Medicine First-episode psychosis Taro Kishi Lecturer, Department of Psychiatry, Fujita University School of Medicine Yuki Matsuda Hospital First Division of Psychiatry, National Center of Neurology and Psychiatry Nobumi Miyake Lecturer, Department of Neuropsychiatry, St. Marianna University School of Medicine Recurrence and relapse Junichi Iga Associate Professor, Department of Neuropsychiatry, Ehime University Graduate School of Medicine Masaki Kato Associate Professor, Department of Neuropsychiatry, Kansai Medical University Aran Tajika Researcher, Department of Health Promotion and Human Behavior, Kyoto University School of Public Health Hikaru Hori Lecturer, Department of Psychiatry, University of Occupational and Environmental Health Maintenance treatment Koki Ito Department of Psychiatry and Behavioral Sciences, Johns Hopkins University/Department of Psychiatry, Hokkaido University Graduate School Tetsufumi Kanazawa Lecturer, Department of Neuropsychiatry, Osaka Medical College Taishiro Kishimoto Specially appointed lecturer, Department of Neuropsychiatry, Keio University School of Medicine Hiroyoshi Takeuchi Department of Psychiatry, University of Toronto/Department of Neuropsychiatry, Keio University School of Medicine Akitoyo Hishimoto Associate Professor, Department of Psychiatry, Kobe University Graduate School of Medicine Treatment resistance Tetsuro Enomoto Chair of Department of Psychiatry, Director of Clinical Trial Management Office, National Center for Global Health and Medicine Kohnodai Hospital Taro Suwa Department of Neuropsychiatry, Kyoto University Graduate School of Medicine Yoshiteru Takekita Department of Biomedical and Neuromotor Sciences, University of Bologna/Department of Neuropsychiatry, Kansai Medical University Ryota Hashimoto Associate Professor, United Graduate School of Child Development, Osaka University/Department of Psychiatry, Osaka University Medical School Fuminari Misawa Director, Yamanashi Prefectural Kita Hospital Ryoji Miyada Assistant Director, Yamanashi Prefectural Kita Hospital Other clinical problems Ken Inada Lecturer, Department of Psychiatry, Tokyo Women's Medical University Hospital Soichiro Sato Assistant Director, Takaoka Hospital Naohisa Tsujino Lecturer, Department of Neuropsychiatry, Toho University Hiroki Yamada Associate Professor, Department of Psychiatry, Showa University Hiroyuki Watanabe Specially Appointed Professor, Center for Forensic Mental Health, Chiba University/Director, Kimura Hospital Task force member roles Chair Person responsible for this guideline Chair/vice-chair Persons who determine the policy of this guideline. Specifically, the Minds method was used. The overall composition was decided as follows: Introduction, Chapter 1: First-episode psychosis, Chapter 2: Recurrence and relapse, Chapter 3: Maintenance treatment, Chapter 4: Treatment resistance, Chapter 5: Other clinical problems. The person in charge of each chapter was determined and members for each chapter were approved. Person in charge of each chapter Person responsible for each chapter. A committee was chosen for each chapter. Chapter 1: Taro Kishi, Chapter 2: Masaki Kato, Chapter 3: Taishiro Kishimoto, Chapter 4: Ryota Hashimoto, Chapter 5: Ken Inada. Members for each chapter The clinical questions (CQs) for each chapter were determined by the person responsible for each chapter. Each chapter consists of an introduction, a recommendation, and an explanation. All members (chair, vice-chair, person in charge of each chapter, members for each chapter) Sufficient discussions were held for each specified CQ and each CQ was approved unanimously as a general rule. CQs with split opinions were put on hold and the person in charge of each chapter created a new proposal that incorporated these opinions, after which a second discussion was held. Each member submitted one vote when no unanimous consensus could be reached and the CQ was approved if over 2/3 of the members voted for it. Cooperation from the Japanese Society of Schizophrenia Research Emi Ikebuchi Professor, Department of Neuropsychiatry, Teikyo University Kiyoto Kasai Professor, Department of Neuropsychiatry, University of Tokyo Masahiro Goto Director, Minamihama Hospital Masato Fukuda Professor, Department of Neuropsychiatry, Gunma University Toshiya Murai Professor, Department of Psychiatry, Kyoto University Conflict-of-interest information The Japanese Society of Neuropsychopharmacology has made every effort to avoid actual or potential conflicts of interest, so that the members may prepare this clinical guideline created by the Society with neutrality and fairness. All members creating this guideline have disclosed actual or potential conflict-of-interest information. The creation of this guideline was funded by a Ministry of Health, Labor and Welfare Science Research Grant. Conflict-of-interest information by the members creating this guideline (as of September 2015) is as follows: Junichi Iga: Received rewards for lectures and manuscript fees for writing from Astellas Pharma Inc., Eisai Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Shionogi & Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Meiji Seika Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., and Janssen Pharmaceutical K.K. Jun Ishigooka: Received research grants, rewards for lectures, manuscript fees for writing, and donations from Arc Medium, Astellas Pharma Inc., AbbVie Inc., Medicine and Drug Journal, Infront Inc., Eisai Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, CareNet, Inc., Kowa Pharmaceutical Co. Ltd., GMJ Inc., Shionogi & Co. Ltd., National Federation of Association of Families with Mental Illness in Japan, Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Chugai Igakusha, Chugai Pharmaceutical Co. Ltd., Tokyo Institute of Psychiatry, Tochigi Prefecture Mental Illness Support Association, Toppan Printing Co. Ltd., Nanzando, Eli Lilly Japan K.K., Japan Medical Association, Japan Medical Journal, Novartis Pharma K.K., Pfizer Inc., Meiji Seika Pharma Co. Ltd., Medical Professional Relations K.K., Mebix Inc., Mochida Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Yoshitomiyakuhin Co., and Life Medicom Co. Ltd. Koki Ito: Received rewards for lectures from Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., and Janssen Pharmaceutical K.K. Ken Inada: Received rewards for lectures and manuscript fees for writing from Arc Medium, Astellas Pharma Inc., AbbVie Inc., Igaku-Shoin Ltd., Medicine and Drug Journal, Eisai Co. Ltd., MSD K.K., M3 Inc., Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Shionogi & Co. Ltd., Seiwa Shoten Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Pfizer Inc., Meiji Seika Pharma Co. Ltd., Medical Review Co. Ltd., Mebix Inc., Mochida Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Nakao Iwata: Received research grants, rewards for lectures, manuscript fees for writing, and donations from Arc Medium, Astellas Pharma Inc., AbbVie Inc., Igaku-Shoin Ltd., Eisai Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Shionogi & Co. Ltd., JUMPs, Sentan Igaku-sha, Daiichi Sankyo Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd., Tsumura & Co., Nikkei NP, Eli Lilly Japan K.K., Nihon Medi-Physics Co. Ltd., Novartis Pharma K.K., Pfizer Inc., For Life Medical Inc., Bracket Co., Meiji Seika Pharma Co. Ltd., Medical Review Co. Ltd., Mebix Inc., Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Tetsuro Enomoto: Received rewards for lectures from Otsuka Pharmaceutical Co. Ltd., Novartis Pharma K.K., Mochida Pharmaceutical Co. Ltd., and Janssen Pharmaceutical K.K. Masaki Kato: Received research grants and rewards for lectures from Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Shionogi & Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Mitsubishi Tanabe Pharma Co., Eli Lilly Japan K.K., Promotion and Mutual Aid Corporation for Private Schools of Japan, Pfizer Inc., Meiji Seika Pharma Co. Ltd., Ministry of Education, Culture, Sports, Science and Technology Scientific Research Fund, Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Tetsufumi Kanazawa: Received rewards for lectures from Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Sumitomo Dainippon Pharma Co. Ltd., Mitsubishi Tanabe Pharma Co., Eli Lilly Japan K.K., Meiji Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Taro Kishi: Received research grants, rewards for lectures, and manuscript fees for writing from Astellas Pharma Inc., AbbVie Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Shionogi & Co. Ltd., Daiichi Sankyo Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Mitsubishi Tanabe Pharma Co., Tsumura & Co., Japanese Society of Schizophrenia Research (Astellas Pharma Inc.), Eli Lilly Japan K.K., the Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research for Young Researchers B, Novartis Pharma K.K., Pfizer Inc., Meiji Seika Pharma Co. Ltd., and Janssen Pharmaceutical K.K. Taishiro Kishimoto: Received rewards for lectures and donations from AbbVie Inc., Eisai Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Shionogi & Co. Ltd., SENSHIN Medical Research Foundation (Mitsubishi Tanabe Pharma Co.), Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Japanese Society of Schizophrenia Research (Astellas Pharma Inc.), Eli Lilly Japan K.K., Novartis Pharma K.K., Pfizer Inc., Pfizer Health Research Foundation, Mochida Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Ichiro Kusumi: Received research grants, rewards for lectures, manuscript fees for writing, and donations from Asahi Kasei Pharma Co., Astellas Pharma Inc., AbbVie Inc., Igaku-Shoin Ltd., Eisai Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., GlaxoSmithKline plc, Shionogi & Co. Ltd., Synergy Medical Communications, Seiwa Shoten Co. Ltd., Daiichi Sankyo Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Nippon Chemiphar Co. Ltd., Boehringer Ingelheim Japan, Novartis Pharma K.K., Pfizer Inc., Meiji Seika Pharma Co. Ltd., Mebix Inc., Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Soichiro Sato: Received rewards for lectures and manuscript fees for writing from Astellas Pharma Inc., Medicine and Drug Journal, MSD K.K., Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Shionogi & Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Tominaga Pharmacy Inc., Nanzando, Eli Lilly Japan K.K., Medical Review Co. Ltd., Mochida Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Taro Suwa: Received rewards for lectures from Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, and Novartis Pharma K.K. Hiroyoshi Takeuchi: Received manuscript fees for writing from Sumitomo Dainippon Pharma Co. Ltd. Yoshiteru Takekita: Received rewards for lectures from Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Meiji Seika Pharma Co. Ltd., and Janssen Pharmaceutical K.K. Aran Tajika: Received rewards for lectures from Mitsubishi Tanabe Pharma Co., and Eli Lilly Japan K.K. Naohisa Tsujino: Received rewards for lectures and manuscript fees for writing from Astellas Pharma Inc., Igaku-Shoin Ltd., Omori Medical Association, Kanehara & Co. Ltd., Shionogi & Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Nanzando, Novartis Pharma K.K., Fujifilm RI Pharma Co. Ltd., Meiji Seika Pharma Co. Ltd., Medical View Co. Ltd., Mochida Pharmaceutical Co. Ltd., and Janssen Pharmaceutical K.K. Atsuo Nakagawa: Received research grants, rewards for lectures, and manuscript fees for writing from Arc Medium, Asahi Kasei Pharma Co., Igaku-Shoin Ltd., NTT Docomo Inc., Otsuka Pharmaceutical Co. Ltd., Kagakuhyoronsya Co. Ltd., National Center of Neurology and Psychiatry, Kongo-shuppan Co., Shionogi & Co. Ltd., Jiho Inc., Shimane Community Medical Care and Career Support Center, Shinjuku Health Center, Seiwa Shoten Co. Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Eli Lilly Japan K.K., Japanese Association for Acute Medicine, Japan Health and Culture Promotion Center, Japanese Society for Child and Adolescent Psychiatry, Meiji Seika Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Yamanashi Prefectural Kita Hospital, Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Ryota Hashimoto: Received rewards for lectures or donations from Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Daiko Advertising Inc., Sumitomo Dainippon Pharma Co. Ltd., Nippon Zoki Pharmaceutical Co., Novartis Pharma K.K., Hisamitsu Pharmaceutical Co. Ltd., Pfizer Inc., Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Akitoyo Hishimoto: Received research grants, rewards for lectures, and manuscript fees for writing from Asubio Pharma Co. Ltd., Eisai Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Shionogi & Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Eli Lilly Japan K.K., Nippon Shinyaku Co. Ltd., Pfizer Inc., and Janssen Pharmaceutical K.K. Hikaru Hori: Received rewards for lectures and manuscript fees for writing from Arc Medium, Asahi Kasei Pharma Co., Astellas Pharma Inc., Eisai Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Seiwa Shoten Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Nakajima Educational Films Publishing Inc., Eli Lilly Japan K.K., Novartis Pharma K.K., Pfizer Inc., Meiji Seika Pharma Co. Ltd., Medical Review Co. Ltd., Mochida Pharmaceutical Co. Ltd., and Janssen Pharmaceutical K.K. Yuki Matsuda: Received research grants, rewards for lectures, and manuscript fees for writing from Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Seiwa Shoten Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Eli Lilly Japan K.K., the Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research for Young Researchers B, Pfizer Inc., Meiji Seika Pharma Co. Ltd., and Life Science Co. Ltd. Fuminari Misawa: Received rewards for lectures from Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., and Pfizer Inc. Nobumi Miyake: Received research grants, rewards for lectures, and gifts from Otsuka Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Japanese Society of Schizophrenia Research (Astellas Pharma Inc.), Eli Lilly Japan K.K., the Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research for Young Researchers B, Novartis Pharma K.K., Meiji Seika Pharma Co. Ltd., and Janssen Pharmaceutical K.K. Ryoji Miyada: Received rewards for lectures and manuscript fees for writing from Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., and Eli Lilly Japan K.K. Seiya Miyamoto: Received rewards for lectures and manuscript fees for writing from Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., and Janssen Pharmaceutical K.K. Hiroki Yamada: Received rewards for lectures and manuscript fees for writing from MSD K.K., Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Sumitomo Dainippon Pharma Co. Ltd., Eli Lilly Japan K.K., Meiji Seika Pharma Co. Ltd., Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Hiroyuki Watanabe: Received rewards for lectures and manuscript fees for writing from Astellas Pharma Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Eli Lilly Japan K.K., Mochida Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Status of Guideline for Pharmacological Therapy of Schizophrenia Task Force meetings October 2013 Approved by the Board of Directors of the Japanese Society of Neuropsychopharmacology October 26, 2013 First MeetingOkinawa Convention Center March 15, 2014 Second meetingEast Building 2F, Audiovisual Training RoomKyoto Terrsa September 13, 2014 Third MeetingFukuracia Shinagawa November 20, 2014 Fourth MeetingNagoya Congress Center December 20, 2014 Fifth MeetingFukuracia Shinagawa Interim reports and public discussions November 22, 2014 Nagoya. 24th Japanese Society of Clinical Neuropsychopharmacology/44th Japanese Soc
Referência(s)